Table 2.

Proportion of participants with genetic antibiotic resistance determinants by antibiotic class by treatment group at 8 weeks from enrollment

	Azithromycin (N = 49)	Amoxicillin (N = 46)	Odds ratio (95% CI)	P value*
Macrolides	32 (65%)	30 (65%)	1.00 (0.43–2.34)	0.99
Beta-lactams	40 (82%)	38 (83%)	0.94 (0.33–2.68)	0.99
Fluoroquinolones	29 (59%)	22 (48%)	1.58 (0.70–3.56)	0.56
Sulfonamides	24 (49%)	14 (30%)	2.19 (0.95–5.09)	0.52
Trimethoprim	38 (78%)	26 (78%)	0.96 (0.36–2.53)	0.99
Tetracyclines	45 (92%)	40 (87%)	1.69 (0.44–6.41)	0.77
Rifampin	19 (39%)	15 (33%)	1.31 (0.56–3.04)	0.77
Aminoglycosides	31 (63%)	23 (50%)	1.72 (0.76–3.91)	0.52
Metronidazole	24 (49%)	29 (63%)	0.56 (0.25–1.28)	0.52
Aminocoumarins	10 (20%)	4 (9%)	2.69 (0.78–9.29)	0.52
Bacitracin	19 (39%)	12 (26%)	1.79 (0.75–4.30)	0.52
Fosfomycins	1 (2%)	2 (4%)	0.46 (0.04–5.23)	0.77
Elfamycins	34 (69%)	27 (59%)	1.60 (0.69–3.71)	0.56
Lipopeptides	2 (4%)	1 (2%)	1.91 (0.17–21.9)	0.80
Phenicol	8 (16%)	7 (15%)	1.09 (0.36–3.28)	0.99
Glycopeptides	0	0	NA	NA
Cationic peptides	30 (61%)	22 (48%)	1.72 (0.76–3.89)	0.52

^*False discovery rate-adjusted P value.